Keros Therapeutics, Inc. Deferred Offering Costs
Keros Therapeutics, Inc. (KROS) had Deferred Offering Costs of $0 as of 2020-12-31, per its 10-K filed 2021-03-25.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2021-03-25
- 2020-12-31: Deferred Offering Costs $0.00.
- 2020-09-30: Deferred Offering Costs $0.00.
- 2020-06-30: Deferred Offering Costs $0.00.
- 2020-03-31: Deferred Offering Costs $2.02M.
| Period end | Deferred Offering Costs |
|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-03-25 |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-10 |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-13 |
| 2020-03-31 | $2.02M 10-Q · filed 2020-05-22 |
| 2019-12-31 | $604.00K 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |